ArticleERJ open research2020
Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study.
Article in ERJ open research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Detection to Disruption: A Comprehensive Review of Bacterial Biofilms and Therapeutic Advances.Antibiotics (Basel, Switzerland) · 2026Review
- Review
- Low Molecular Weight Alginate Oligosaccharides as Alternatives to PEG for Enhancement of the Diffusion of Cationic Nanoparticles Through Cystic Fibrosis Mucus.Advanced healthcare materials · 2025Article
- Biofilm Production and Its Implications in Pediatrics.Microorganisms · 2024Review
- Bioarchitectural Design of Bioactive Biopolymers: Structure-Function Paradigm for Diabetic Wound Healing.Biomimetics (Basel, Switzerland) · 2024Review
- New Antimicrobial Strategies to Treat Multi-Drug Resistant Infections Caused by Gram-Negatives in Cystic Fibrosis.Antibiotics (Basel, Switzerland) · 2024Review
- Mucin adhesion of serial cystic fibrosis airwaysFrontiers in cellular and infection microbiology · 2024Article
- Structure-Activity Relationships of Low Molecular Weight Alginate Oligosaccharide Therapy againstBiomolecules · 2023Article
- Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis.Pharmaceutics · 2023Review
- How Three Self-Secreted Biofilm Exopolysaccharides ofInternational journal of molecular sciences · 2023Review
- The alginate polymer OligoG alters susceptibility of biofilm-embedded non-typeableJAC-antimicrobial resistance · 2023Article
- Alginate oligosaccharides enhance the antifungal activity of nystatin against candidal biofilms.Frontiers in cellular and infection microbiology · 2023Article
- Characterization of a Novel Polysaccharide Lyase Family 5 Alginate Lyase with PolyM Substrate Specificity.Foods (Basel, Switzerland) · 2022Article
- Human Milk Oligosaccharides: Potential Applications in COVID-19.Biomedicines · 2022Review
- Pseudomonas aeruginosa in the Cystic Fibrosis Lung.Advances in experimental medicine and biology · 2022Article
- What Is New in the Anti-Frontiers in cellular and infection microbiology · 2022Review
- Approaches to Targeting Bacterial Biofilms in Cystic Fibrosis Airways.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 9 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOligoG is a low molecular-weight alginate oligosaccharide that improves the viscoelastic properties of cystic fibrosis (CF) mucus and disrupts biofilms, thereby potentiating the activity of antimicrobial agents. The efficacy of inhaled OligoG was evaluated in adult patients with CF.
methodsA randomised, double-blind, placebo-controlled multicentre crossover study was used to demonstrate safety and efficacy of inhaled dry powder OligoG. Subjects were randomly allocated to receive OligoG 1050 mg per day (10 capsules three times daily) or matching placebo for 28 days, with 28-day washout periods following each treatment period. The primary end-point was absolute change in percentage predicted forced expiratory volume in 1 s (FEV
resultsIn this study, 90 adult subjects were screened and 65 were randomised. Statistically significant improvement in FEV
conclusionsInhalation of OligoG-dry powder over 28 days was safe in adult CF subjects. Statistically significant improvement of FEV
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.